Are we nearly there yet? Coverage and compliance of mass drug administration for lymphatic filariasis elimination.
Identifieur interne : 001097 ( PubMed/Curation ); précédent : 001096; suivant : 001098Are we nearly there yet? Coverage and compliance of mass drug administration for lymphatic filariasis elimination.
Auteurs : Neal D E. Alexander [Royaume-Uni]Source :
- Transactions of the Royal Society of Tropical Medicine and Hygiene [ 1878-3503 ] ; 2015.
Descripteurs français
- KwdFr :
- MESH :
- administration et posologie : Diéthylcarbamazine, Filaricides.
- organisation et administration : Mise en oeuvre des programmes de santé.
- Filariose lymphatique, Humains, Éradication de maladie.
English descriptors
- KwdEn :
- MESH :
- chemical , administration & dosage : Diethylcarbamazine, Filaricides.
- organization & administration : Health Plan Implementation.
- prevention & control : Elephantiasis, Filarial.
- Disease Eradication, Humans.
Abstract
Lymphatic filariasis has been targeted for elimination by 2020, and a threshold of 65% coverage of mass drug administration (MDA) has been adopted by the Global Programme to Eliminate Lymphatic Filariasis (GPELF). A recent review by Babu and Babu of 36 studies of MDA for lymphatic filariasis in India found that coverage, defined as receipt of tablets, ranged from 48.8 to 98.8%, while compliance, defined as actual ingestion of tablets, was 22% lower on average. Moreover, the denominator for these coverage figures is the eligible, rather than total, population. By contrast, the 65% threshold, in the original modelling study, refers to ingestion of tablets in the total population. This corresponds to GPELF's use of 'epidemiological drug coverage' as a trigger for the Transmission Assessment Surveys (TAS), which indicate whether to proceed to post-MDA surveillance. The existence of less strict definitions of 'coverage' should not lead to premature TAS that could impair MDA's sustainability.
DOI: 10.1093/trstmh/tru204
PubMed: 25575555
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001097
Links to Exploration step
pubmed:25575555Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Are we nearly there yet? Coverage and compliance of mass drug administration for lymphatic filariasis elimination.</title><author><name sortKey="Alexander, Neal D E" sort="Alexander, Neal D E" uniqKey="Alexander N" first="Neal D E" last="Alexander">Neal D E. Alexander</name><affiliation wicri:level="1"><nlm:affiliation>MRC Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK neal.alexander@lshtm.ac.uk.</nlm:affiliation><country wicri:rule="url">Royaume-Uni</country><wicri:regionArea>MRC Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25575555</idno><idno type="pmid">25575555</idno><idno type="doi">10.1093/trstmh/tru204</idno><idno type="wicri:Area/PubMed/Corpus">001097</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001097</idno><idno type="wicri:Area/PubMed/Curation">001097</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001097</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Are we nearly there yet? Coverage and compliance of mass drug administration for lymphatic filariasis elimination.</title><author><name sortKey="Alexander, Neal D E" sort="Alexander, Neal D E" uniqKey="Alexander N" first="Neal D E" last="Alexander">Neal D E. Alexander</name><affiliation wicri:level="1"><nlm:affiliation>MRC Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK neal.alexander@lshtm.ac.uk.</nlm:affiliation><country wicri:rule="url">Royaume-Uni</country><wicri:regionArea>MRC Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT</wicri:regionArea></affiliation></author></analytic><series><title level="j">Transactions of the Royal Society of Tropical Medicine and Hygiene</title><idno type="eISSN">1878-3503</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Diethylcarbamazine (administration & dosage)</term><term>Disease Eradication</term><term>Elephantiasis, Filarial (prevention & control)</term><term>Filaricides (administration & dosage)</term><term>Health Plan Implementation (organization & administration)</term><term>Humans</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Diéthylcarbamazine (administration et posologie)</term><term>Filaricides (administration et posologie)</term><term>Filariose lymphatique ()</term><term>Humains</term><term>Mise en oeuvre des programmes de santé (organisation et administration)</term><term>Éradication de maladie</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Diethylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Diéthylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="organisation et administration" xml:lang="fr"><term>Mise en oeuvre des programmes de santé</term></keywords><keywords scheme="MESH" qualifier="organization & administration" xml:lang="en"><term>Health Plan Implementation</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Disease Eradication</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Filariose lymphatique</term><term>Humains</term><term>Éradication de maladie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Lymphatic filariasis has been targeted for elimination by 2020, and a threshold of 65% coverage of mass drug administration (MDA) has been adopted by the Global Programme to Eliminate Lymphatic Filariasis (GPELF). A recent review by Babu and Babu of 36 studies of MDA for lymphatic filariasis in India found that coverage, defined as receipt of tablets, ranged from 48.8 to 98.8%, while compliance, defined as actual ingestion of tablets, was 22% lower on average. Moreover, the denominator for these coverage figures is the eligible, rather than total, population. By contrast, the 65% threshold, in the original modelling study, refers to ingestion of tablets in the total population. This corresponds to GPELF's use of 'epidemiological drug coverage' as a trigger for the Transmission Assessment Surveys (TAS), which indicate whether to proceed to post-MDA surveillance. The existence of less strict definitions of 'coverage' should not lead to premature TAS that could impair MDA's sustainability.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25575555</PMID><DateCreated><Year>2015</Year><Month>02</Month><Day>10</Day></DateCreated><DateCompleted><Year>2015</Year><Month>05</Month><Day>21</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-3503</ISSN><JournalIssue CitedMedium="Internet"><Volume>109</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Transactions of the Royal Society of Tropical Medicine and Hygiene</Title><ISOAbbreviation>Trans. R. Soc. Trop. Med. Hyg.</ISOAbbreviation></Journal><ArticleTitle>Are we nearly there yet? Coverage and compliance of mass drug administration for lymphatic filariasis elimination.</ArticleTitle><Pagination><MedlinePgn>173-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/trstmh/tru204</ELocationID><Abstract><AbstractText>Lymphatic filariasis has been targeted for elimination by 2020, and a threshold of 65% coverage of mass drug administration (MDA) has been adopted by the Global Programme to Eliminate Lymphatic Filariasis (GPELF). A recent review by Babu and Babu of 36 studies of MDA for lymphatic filariasis in India found that coverage, defined as receipt of tablets, ranged from 48.8 to 98.8%, while compliance, defined as actual ingestion of tablets, was 22% lower on average. Moreover, the denominator for these coverage figures is the eligible, rather than total, population. By contrast, the 65% threshold, in the original modelling study, refers to ingestion of tablets in the total population. This corresponds to GPELF's use of 'epidemiological drug coverage' as a trigger for the Transmission Assessment Surveys (TAS), which indicate whether to proceed to post-MDA surveillance. The existence of less strict definitions of 'coverage' should not lead to premature TAS that could impair MDA's sustainability.</AbstractText><CopyrightInformation>© The Author 2015. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alexander</LastName><ForeName>Neal D E</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>MRC Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK neal.alexander@lshtm.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/K012126/1</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>01</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trans R Soc Trop Med Hyg</MedlineTA><NlmUniqueID>7506129</NlmUniqueID><ISSNLinking>0035-9203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005369">Filaricides</NameOfSubstance></Chemical><Chemical><RegistryNumber>V867Q8X3ZD</RegistryNumber><NameOfSubstance UI="D004049">Diethylcarbamazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2013 Nov;7(11):e2447</RefSource><PMID Version="1">24278486</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2003 Nov 1;188(9):1371-81</RefSource><PMID Version="1">14593597</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Wkly Epidemiol Rec. 2012 Nov 30;87(48):478-82</RefSource><PMID Version="1">23213667</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2011 Oct;5(10):e1346</RefSource><PMID Version="1">22022627</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trans R Soc Trop Med Hyg. 2014 May;108(5):249-51</RefSource><PMID Version="1">24699360</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trans R Soc Trop Med Hyg. 2014 Sep;108(9):538-49</RefSource><PMID Version="1">24728444</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2012;6(11):e1926</RefSource><PMID Version="1">23209865</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Wkly Epidemiol Rec. 2014 Sep 19;89(38):409-18</RefSource><PMID Version="1">25243263</PMID></CommentsCorrections><CommentsCorrections RefType="CommentOn"><RefSource>Trans R Soc Trop Med Hyg. 2014 Sep;108(9):538-49</RefSource><PMID Version="1">24728444</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D004049" MajorTopicYN="N">Diethylcarbamazine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060740" MajorTopicYN="Y">Disease Eradication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005369" MajorTopicYN="N">Filaricides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006284" MajorTopicYN="N">Health Plan Implementation</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization & administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4321021</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Elimination</Keyword><Keyword MajorTopicYN="N">Lymphatic filariasis</Keyword><Keyword MajorTopicYN="N">Mass drug administration</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25575555</ArticleId><ArticleId IdType="pii">tru204</ArticleId><ArticleId IdType="doi">10.1093/trstmh/tru204</ArticleId><ArticleId IdType="pmc">PMC4321021</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001097 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001097 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:25575555
|texte= Are we nearly there yet? Coverage and compliance of mass drug administration for lymphatic filariasis elimination.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:25575555" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |